http://www.raqualia.com/

NEWS RELEASE

RaQualia to Initiate Phase I Clinical Trial for 5-HT_{2B} Antagonist in UK

June 1, 2015 - RaQualia Pharma Inc. (RaQualia) today announced that the company's board of directors passed a resolution of authorizing the initiation of Phase I clinical trial for 5-HT_{2B} antagonist (RQ-00310941) in the United Kingdom.

Since the start of preclinical development for RQ-00310941 in April 2012, RaQualia has conducted pharmacology and pharmacokinetics studies based on reliability criteria, and carried out toxicity and safety testing pursuant to Good Laboratory Practice (GLP). The data collected through these studies have shown to be compelling enough to initiate a First-In-Human study.

The objective of the Phase I clinical trial is to investigate safety, tolerability and pharmacokinetics of RQ-00310941 in healthy subjects, and to evaluate how food and gender differences affect these profiles. The study is also designed to dose a small group of patients to examine the effect on abdominal symptoms. By collecting data from the patients, the company aims to verify the proof of principle (PoP) for pharmacological effects of RQ-00310941.

In animal models, RQ-00310941 attenuated visceral hypersensitivity and inhibited abnormal defecation. Therefore, RQ-00310941 is expected to relieve the symptoms such as abdominal pain or discomfort, and abnormal bowel movements associated with lower gastrointestinal diseases.

RaQualia will continue to accelerate its licensing activities globally, maximizing the value of its development compounds by establishing proof-of-concept at early development stages.

The business performance for FY 2015 issued on May 14, 2015, will not be affected by this announcement. The revised financial forecasts will be published as soon as it is recognized.

Contact:
E-mail address: ir@raqualia.com
URL: www.raqualia.com

####